• Pacira Biosciences agreed to divest its iovera business to Zimmer Biomet in a deal valued at up to USD 140 million.
• Consideration includes USD 70 million upfront, with up to USD 70 million in revenue-based milestones through Dec. 31, 2031.
• Zimmer Biomet will acquire rights to develop, manufacture, and commercialize iovera, an FDA-cleared cryoneurolysis pain device.
• Companies will collaborate on the spasticity program, with potential additional compensation tied to study completion and regulatory approval.
• Closing is expected in Q3 2026; upfront net proceeds earmarked for balance sheet support, including paying down a senior secured revolving credit facility.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacira Biosciences Inc. published the original content used to generate this news brief on June 30, 2026, and is solely responsible for the information contained therein.